COST-EFFECTIVENESS ANA LYSIS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY OF EARLY-STAGE HER2-POSITIVE BREAST CANCER

被引：1
|
作者：
Nguyen, T. T. C. [1 ]
Nguyen, T. T. T. [2 ]
机构：
[1] Univ Med & Pharm HCMC, HCMC, Ho Chi Minh City, Vietnam
[2] Univ Med & Pharm HCMC, Ho Chi Minh City, Vietnam
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.107
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN16
引用
收藏
页码：A735 / A735
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A. U.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A165 - A165
  • [2] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [3] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [4] Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
    Quintyne, K. I.
    Woulfe, B.
    Dee, A.
    Gupta, R.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    [J]. PLOS ONE, 2019, 14 (06):
  • [6] Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
    Lidgren, M.
    Joensson, B.
    Rehnberg, C.
    Willking, N.
    Bergh, J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (03) : 487 - 495
  • [7] POTENTIAL COST-EFFECTIVENESS OF NERATINIB FOLLOWING TRASTUZUMAB THERAPY FOR TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Schwartz, N. R.
    Steuten, L.
    Babigumira, J. B.
    Roth, J. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [8] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Pienkowski, T.
    Drosik, K.
    Gyldmark, M.
    Aultman, R.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [9] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    Guerrero, Anna Melissa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [10] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Anne Julienne Genuino
    Usa Chaikledkaew
    Anna Melissa Guerrero
    Thanyanan Reungwetwattana
    Ammarin Thakkinstian
    [J]. BMC Health Services Research, 19
12345